Many clinical randomized controlled trials prove the efficacy of cytokine inhibitors that manipulate IL-17 and related pathways in the management of psoriasis, rheumatoid arthritis, and inflammatory bowel disease. The gene discussed is IL17A; the disease is rheumatoid arthritis.